Here's a step in the direction of individualizing chemotherapy choices.
A small study published in this month's Annals of Oncology
, "Platinum-based chemotherapy in triple-negative breast cancer
," supports earlier findings that women with triple-negative (TN) breast cancer may be more likely than other patients to respond to one of the platinum chemotherapy drugs, Carboplatin and Cisplatin.
In the study, the response rates of women with TN and other forms of breast cancer were compared after treatment with platinum chemotherapy. Some of these patients had locally advanced breast cancer and some were being treated for metastatic disease, but in both groups, the TN patients responded significantly better.Annals of Oncology 2008 19(11):1847-185Platinum-based chemotherapy in triple-negative breast cancer
B. Sirohi, Smith, I. et al. Breast Unit, Royal Marsden NHS Foundation Trust, London. E-mail for reprint: email@example.comBackground:
Experimental data suggest that triple-negative (TN) breast cancer may have increased sensitivity to platinum-based chemotherapy but clinical data are limited. We present our long-term results with platinum-based chemotherapy for TN breast cancer.Patients and methods
: In all, 94 (17 TN), 79 (11 TN) and 155 (34 TN) patients receiving platinum-based chemotherapy in neo-adjuvant/adjuvant and advanced setting were included. Response rates and outcome were compared for TN tumours versus others.Results
: Neo-adjuvant complete response rates were significantly higher for TN tumours (88%) than others (51%; P = 0.005). The 5-year overall survival (OS) for TN tumours following adjuvant/neo-adjuvant chemotherapy was 64% [95% confidence interval (CI) 44% to 79%] compared with 85% (95% CI 79% to 90%) for others. Five-year disease-free survival for TN tumours was 57% (95% CI 37% to 73%) compared with 72% (95% CI 64% to 78%) for others. For patients with advanced breast cancer, overall response rates were 41% for TN tumours and 31% for others (P = 0.3). Patients with TN tumours had a significantly prolonged progression-free survival of 6 months compared with 4 months for others (P = 0.05), though the OS was not significantly different between the two groups (11 versus 7 months).Conclusion
: Platinum-based chemotherapy achieves increased response rates for TN tumours, with a trend towards worse survival in early breast cancer through an improved survival in advanced disease. Prospective randomised trials are warranted.